Nortriptyline
Nortriptyline, Pamelor (nortriptyline) is a small molecule pharmaceutical. Nortriptyline was first approved as Aventyl hydrochloride on 1982-01-01. It is used to treat anxiety disorders, attention deficit disorder with hyperactivity, depressive disorder, enuresis, and pain amongst others in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target G protein-activated inward rectifier potassium channel 2, ATP-sensitive inward rectifier potassium channel 10, and G protein-activated inward rectifier potassium channel 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Nortriptyline (discontinued: Aventyl, Nortriptyline, Pamelor)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nortriptyline hydrochloride
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nortriptyline hci | ANDA | 2022-10-05 |
| nortriptyline hci nortriptyline hcl | ANDA | 2019-03-11 |
| nortriptyline hcl | ANDA | 2024-08-27 |
| nortriptyline hydrochloride | ANDA | 2024-12-18 |
| pamelor | New Drug Application | 2024-12-04 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
60 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | 2 | 2 | 12 | 10 | 26 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | 3 | — | 10 | 5 | 18 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 2 | — | 7 | 2 | 11 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | 3 | 1 | 4 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | 2 | 1 | 4 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | 1 | 1 | 3 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | 2 | 1 | 3 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | 1 | 2 | 1 | — | 3 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | 1 | — | 2 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 2 | — | 2 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | 1 | — | 2 | 3 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | — | — | 2 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Herpes zoster | D006562 | EFO_0006510 | B02 | — | — | 1 | — | — | 1 |
| Heartburn | D006356 | — | R12 | — | — | 1 | — | — | 1 |
| Non-erosive reflux disease | D000096663 | — | — | — | — | 1 | — | — | 1 |
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sciatica | D012585 | HP_0011868 | M54.3 | — | 1 | — | — | 1 | 2 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 2 | — | — | — | 2 |
| Temporomandibular joint disorders | D013705 | — | M26.6 | — | 2 | — | — | — | 2 |
| Tension-type headache | D018781 | HP_0012228 | G44.2 | — | 1 | — | — | 1 | 2 |
| Temporomandibular joint dysfunction syndrome | D013706 | — | — | — | 2 | — | — | — | 2 |
| Syndrome | D013577 | — | — | — | 2 | — | — | — | 2 |
| Radiculopathy | D011843 | — | M54.1 | — | 1 | — | — | 1 | 2 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 2 | — | — | — | 2 |
| Vulvodynia | D056650 | — | N94.81 | — | 1 | — | — | — | 1 |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
| Small cell carcinoma | D018288 | — | — | 1 | — | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | 1 | — | — | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | — | — | — | — | 1 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 4 | 4 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 1 | 1 |
| Spinal stenosis | D013130 | EFO_0007490 | M48.0 | — | — | — | — | 1 | 1 |
| Hernia | D006547 | HP_0100790 | K40-K46 | — | — | — | — | 1 | 1 |
| Intervertebral disc displacement | D007405 | EFO_1001800 | — | — | — | — | — | 1 | 1 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | — | 1 | 1 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | — | — | — | 1 | 1 |
| Intractable pain | D010148 | — | — | — | — | — | — | 1 | 1 |
| Abdominal pain | D015746 | HP_0002027 | R10.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nortriptyline |
| INN | nortriptyline |
| Description | Nortriptyline is an organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline. It has a role as a drug metabolite, an antidepressant, an adrenergic uptake inhibitor, an analgesic, an antineoplastic agent and an apoptosis inducer. It is an organic tricyclic compound and a secondary amine. It is functionally related to an amitriptyline. It derives from a hydride of a dibenzo[a,d][7]annulene. |
| Classification | Small molecule |
| Drug class | antidepressants (dibenzol[a,d]cycloheptane derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNCCC=C1c2ccccc2CCc2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 72-69-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL445 |
| ChEBI ID | 7640 |
| PubChem CID | 4543 |
| DrugBank | DB00540 |
| UNII ID | BL03SY4LXB (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Nortriptyline
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,348 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nortriptyline hci, Nortriptyline hcl, Nortriptyline hydrochloride, Pamelor
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,272 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use